{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"2"}],"units":"Participants"}],"description":"(1) Grade 4 neutropenia (ANC \\<500/cumm\\^3) or thrombocytopenia ≧7 days; (2) Hematologic toxicities ≧ Grade 3, eg. febrile neutropenia \\<1,000/cumm\\^3, or platelet count \\<25,000/cumm\\^3 with hemorrhage ≧ 7 days; (3) Non-hematologic toxicities ≧ grade 3, eg. ALT or AST, ≧ 7days; other non-hematologic toxicities ≧ grade 3 (except alopecia, non-chemotherapy related nausea/vomiting); (4) Neurologic toxicities ≧ grade 2, eg. dizziness, or lethargy ≧ 3 days","groups":[{"description":"trientine dihydrochloride PO daily plus pegylated liposomal doxorubicin IV D1 plus carboplatin IV D1\n\ntrientine dihydrochloride: trientine dihydrochloride 300MG/CAPSUE PO daily (at 1st dose level: 300mg)\n\npegylated liposomal doxorubicin: pegylated liposomal doxorubicin 40mg/m2 IV D1\n\ncarboplatin: carboplatin AUC 4 IV D1","id":"OG000","title":"Trientine With Chemotherapy at Dose Level 1 (300mg/d)"},{"description":"rientine dihydrochloride PO daily plus pegylated liposomal doxorubicin IV D1 plus carboplatin IV D1\n\ntrientine dihydrochloride: trientine dihydrochloride 300MG/CAPSUE PO daily (at 2nd dose level: 600mg)\n\npegylated liposomal doxorubicin: pegylated liposomal doxorubicin 40mg/m2 IV D1\n\ncarboplatin: carboplatin AUC 4 IV D1","id":"OG001","title":"Trientine With Chemotherapy at Dose Level 2 (600mg/d)"},{"description":"trientine dihydrochloride PO daily plus pegylated liposomal doxorubicin IV D1 plus carboplatin IV D1\n\ntrientine dihydrochloride: trientine dihydrochloride 300MG/CAPSUE PO daily (at 3rd dose level: 900mg)\n\npegylated liposomal doxorubicin: pegylated liposomal doxorubicin 40mg/m2 IV D1","id":"OG002","title":"Trientine With Chemotherapy at Dose Level 3 (900mg/d)"},{"description":"trientine dihydrochloride PO daily plus pegylated liposomal doxorubicin IV D1 plus carboplatin IV D1\n\ntrientine dihydrochloride: trientine dihydrochloride 300MG/CAPSUE PO daily (at 4th dose level: 1200mg)\n\npegylated liposomal doxorubicin: pegylated liposomal doxorubicin 40mg/m2 IV D1\n\ncarboplatin: carboplatin AUC 4 IV D1","id":"OG003","title":"Trientine With Chemotherapy at Dose Level 4 (1200mg/d)"},{"description":"trientine dihydrochloride PO daily plus pegylated liposomal doxorubicin IV D1 plus carboplatin IV D1\n\ntrientine dihydrochloride: trientine dihydrochloride 300MG/CAPSUE PO daily (at 5th dose level: 1500mg)\n\npegylated liposomal doxorubicin: pegylated liposomal doxorubicin 40mg/m2 IV D1\n\ncarboplatin: carboplatin AUC 4 IV D1","id":"OG004","title":"Trientine With Chemotherapy Dose Level 5 (1500mg/d)"},{"description":"trientine dihydrochloride PO daily plus pegylated liposomal doxorubicin IV D1 plus carboplatin IV D1\n\ntrientine dihydrochloride: trientine dihydrochloride 300MG/CAPSUE PO daily (at 6th dose level: 1800mg)\n\npegylated liposomal doxorubicin: pegylated liposomal doxorubicin 40mg/m2 IV D1\n\ncarboplatin: carboplatin AUC 4 IV D1","id":"OG005","title":"Trientine With Chemotherapy Dose Level 6 (1800mg/d)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"One participant receiving 600 mg/day declined the trial drugs and did not proceed with treatment.Therefore, an additional participant was included at the same dose level.","reportingStatus":"POSTED","timeFrame":"36 days","title":"Number of Participants With Dose-Limiting Toxicity (DLT)","type":"PRIMARY","unitOfMeasure":"Participants"}